We present the case of a 23-year-old 
Introduction

Minimal-change disease (MCD) is a common cause of steroid-resistant nephrotic syndrome (SRNS), and no standard therapies have been firmly established yet. The pathophysiology of minimal-change nephrotic syndrome (MCNS) remains poorly understood (1). Recently, it was reported that rituximab (an anti-CD20 monoclonal antibody) has been successfully used to treat patients with several renal diseases (2).
We 
Discussion
The rationale for using immunosuppressants in the treatment of MCNS is based on the pathophysiology of MCNS, which is considered to be an immune disorder in which a permeability factor, possibly produced by T lymphocytes, induces albuminuria (1). Although MCNS is not antibodymediated disease, B lymphocytes play an important role as immunoregulatory cells by both antigen presentation and cytokine release. Although steroids remain the cornerstone of treatment, various other immunosuppressants have proved effective in preventing relapses and decreasing steroid dependency (3). CyA administration might play a role in reducing the frequency and severity of steroid toxicity. However, several reports have indicated that protracted use of CyA is also sometimes associated with chronic renal injury and hypertension, and development of malignant tumors has been reported in some patients with INS treated with CyA (4). Previous reports have shown that mizoribine therapy appears to be effective for reducing the CsA exposure level as well as decreasing the frequency of relapses in patients with SDNS and SRNS who are also CsA-dependent (5). The rapid improvement of hypercholesterolemia in response to LDL-A therapy suggests a new approach to achieving a high rate of improvement in the severity of SRNS (6). One previous report has suggested that MMF therapy might be effective in SRNS patients in whom other immunosuppressant therapy has failed (7). However, neither mizoribine, LDL-A or MMF had any beneficial effects in the present patient.
We then decided to administer rituximab. Recent studies have reported that rituximab therapy may be used successfully in patients with renal disease (2) . In a previous study, children with INS responded well to rituximab therapy (8) .
The case of a 23-year-old man who suffered from 12 relapses of MCNS was reported recently, in whom long-term remission was achieved only with a standard dosing regimen
F i g u r e 2 . Cl i n i c a l c o u r s e o f t h e p a t i e n t a t o u r h o s p i t a l . of rituximab (375 mg/m 2 every week for 4 weeks) after failure of successive treatments with all other currently available medications for MCNS (9). In most studies, rituximab has generally been prescribed at the dose for which it was developed and licensed for the treatment of B cell nonHodgkin's lymphoma (NHL), 375 mg/m
2 weekly for 4 consecutive weeks (10) 
